Oxytetracycline Capsules

Tetracycline antibiotics. This product is a broad-spectrum antibacterial agent. Many Rickettsia, Mycoplasma, Chlamydia, and Spirochete are sensitive to this product. Enterococci are resistant to it. Others such as Actinomycetes, Bacillus anthracis, Listeria monocytogenes, Clostridium, Nocardia, Vibrio, Brucella, Campylobacter, Yersinia, etc. are also sensitive to this product. Due to the widespread use of oxytetracycline and tetracyclines over the years, common clinical pathogens have serious resistance to oxytetracycline, including Gram-positive bacteria such as Staphylococcus and most Gram-negative bacteria. There is cross-resistance between this product and different varieties of tetracycline antibiotics. The mechanism of action of this product is that the drug can specifically bind to the A position of the bacterial ribosome 30S subunit, inhibiting the growth of the peptide chain and affecting the synthesis of bacterial proteins.

The main ingredient of this product is oxytetracycline, and its chemical name is: 6-methyl-4-(dimethylamino)-3,5,6,10,12,12a-hexahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-2-naphthacenecarboxamide.

This product is in the form of capsules.

1 This product can be used as an optional drug for the following diseases: (1) Rickettsial diseases, including epidemic typhus, endemic typhus, Rocky Mountain fever, scrub typhus and Q fever. (2) Mycoplasma infections. (3) Chlamydia infections, including psittacosis, venereal diseases, lymphoedema, nonspecific urethritis, salpingitis, cervicitis and trachoma. (4) Relapsing fever. (5) Brucellosis. (6) Cholera. (7) Tularemia. (8) Plague. (9) Chancroid. It should be used in combination with aminoglycosides to treat brucellosis and plague. 2 Since common pathogens are currently resistant to this product,

Oral administration: 1.5-2g per day for adults, divided into 3-4 times; 30-40mg/kg per day for children over 8 years old, divided into 3-4 times. This product is contraindicated for children under 8 years old.

1 Digestive system: Gastrointestinal symptoms such as nausea, vomiting, upper abdominal discomfort, abdominal distension, diarrhea, and occasional reports of pancreatitis, esophagitis, and esophageal ulcers, mostly occur in patients who are bedridden immediately after taking the medicine. 2 Hepatotoxicity: Usually fatty liver degeneration. Pregnant women and patients with pre-existing renal impairment are prone to hepatotoxicity, but hepatotoxicity can also occur in patients without the above conditions. 3 Allergic reactions: Mostly maculopapular rashes and erythema. In addition, urticaria, angioedema, allergic purpura, pericarditis, and exacerbation of systemic lupus erythematosus can be seen. Exfoliative dermatitis is not common. Occasionally, anaphylactic shock and asthma occur. Some patients using tetracycline have photosensitivity when exposed to the sun. Therefore, patients should be advised not to expose directly

Patients with a history of allergy to tetracyclines are contraindicated.

1 When used with antacids such as sodium bicarbonate, the absorption of this product may be reduced and its activity may be reduced due to the increase in gastric pH. Therefore, antacids should not be taken within 1 to 3 hours after taking this product. 2 Drugs containing metal ions such as calcium, magnesium, and iron may form insoluble complexes with this product, reducing the absorption of this product after oral administration. 3 When used in combination with the general anesthetic methoxyflurane, its nephrotoxicity may be enhanced. 4 When used in combination with strong diuretics such as furosemide, renal damage may be aggravated. 5 When used in combination with other hepatotoxic drugs (such as anti-tumor chemotherapy drugs), liver damage may be aggravated. 6 The lipid-lowering drugs colestyramine or colestipol may affect the absorption of this product.

Keep away from light, sealed and stored in a dry place.

0.25g

Xi'an Rejoy Jinghua Pharmaccutical Co., Ltd.

• Founded in:

  2000-09-30

• Address:

  No. 16 Hongguang Road, Xi'an

• Tax NO.:

  91610104220766032Y

• Registered Funds:

  14.64 million yuan

• Website:

  Log in to view

• Email:

  Log in to view